Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials

Table 1 Proposed benefits of peritoneal dialysis therapy for heart failure

Continuous gentle ultrafiltration with minimal impact on hemodynamic status

Improvement in functional status and symptoms of volume overload

Reduction in number of days of heart failure-related hospitalizations

Restoration of diuretic responsiveness

Reduction in weight and improvement in volume status

Improvement in left ventricular ejection fraction

Sodium sieving effect and possibility of better control of natremia

Removal of pro-inflammatory mediators (medium-sized molecules)

Reduction in intra-abdominal pressure in patients with severe ascites

Improvement in quality of life

Improved atherogenic lipid serum profile

Lack of impact on neurohormonal activity (renin-angiotensin-aldosterone system and sympathetic nervous system)

Improved control of serum potassium level (hence providing the opportunity to use medications such as aldosterone receptor blockers)

Reduction in healthcare cost

Adapted from Courivaud et al[9], with permission.